Reduced mitochondrial priming, by displacing pro-apoptotic proteins from drug-targeted BCL-2 to non-targeted MCL-1 also induces resistance to BCL-2 antagonists in AML cells14. This evidence concerns the gene BCL2 and acute myeloid leukemia.